PMID- 36552708
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221225
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 11
IP  - 12
DP  - 2022 Dec 19
TI  - The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of 
      Diabetic Cardiomyopathy.
LID - 10.3390/antiox11122500 [doi]
LID - 2500
AB  - According to the 2021 report of the International Diabetes Federation (IDF), 
      there have been approximately 573 million cases of type 2 diabetes mellitus 
      (T2DM) among adults, which sets the disease as a major concern in healthcare 
      worldwide. The development of T2DM is strongly promoted by unhealthy lifestyle 
      factors associated with urbanization and western civilization. The disease is 
      associated with a broad list of systemic complications that can result in 
      premature death, disability and significantly reduced quality of life. The most 
      dramatic in their consequences are cardiovascular complications of T2DM. Our work 
      focuses on one such complication that is specific for diabetes, named diabetic 
      cardiomyopathy (DC). In this condition cardiac dysfunction occurs despite the 
      absence of underlying hypertension, coronary artery disease and valvular disease, 
      which suggest a leading role for metabolic disturbances as a cause. We aimed to 
      establish the role of relatively new hypoglycaemic drugs that have taken the 
      medical world by storm with their broad pleiotropic effects-SGLT-2 inhibitors-in 
      the prevention and treatment of DC at any stage.
FAU - Kowalska, Klaudia
AU  - Kowalska K
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Wilczopolski, Piotr
AU  - Wilczopolski P
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Bulawska, Dominika
AU  - Bulawska D
AUID- ORCID: 0000-0002-2203-6739
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Mlynarska, Ewelina
AU  - Mlynarska E
AUID- ORCID: 0000-0002-6799-4746
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Rysz, Jacek
AU  - Rysz J
AD  - Department of Nephrology, Hypertension and Family Medicine, Medical University of 
      Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
FAU - Franczyk, Beata
AU  - Franczyk B
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221219
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC9774735
OTO - NOTNLM
OT  - AGEs
OT  - NADPH oxidase
OT  - SGLT2is
OT  - diabetes
OT  - diabetic cardiomyopathy
OT  - heart failure
OT  - insulin resistance
OT  - lipotoxicity
OT  - mitochondria
OT  - oxidative stress
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/19
CRDT- 2022/12/23 01:17
PHST- 2022/10/30 00:00 [received]
PHST- 2022/11/30 00:00 [revised]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2022/12/23 01:17 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/19 00:00 [pmc-release]
AID - antiox11122500 [pii]
AID - antioxidants-11-02500 [pii]
AID - 10.3390/antiox11122500 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2022 Dec 19;11(12):2500. doi: 10.3390/antiox11122500.